Yong Wu, M.D., Ph.D., holds faculty positions at David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also an Associate Professor and Core Director for the Drug Discovery Program in Charles Drew University of Medicine and Science. Dr. Wu has a broad background in pharmacology, molecular and cellular biology of diabetes and cancer, and has experiences in anti-cancer drug design and discovery. He is a member of the American Association for Cancer Research and American Heart Association, among others.
Currently, He is engaged in investigating the links between metabolic syndrome and cancer, specifically focusing on the fundamental mechanisms by which elevated blood glucose and fatty acids increase breast cancer risk and progression. This is a key area of interest in the Division of Cancer Research and Training. His current research has also been focused on (1) elucidating a safe and effective therapeutic strategy to preferentially kill the malignant cells that are dependent on glycolytic pathway with a minor effect on normal cells; (2) Design, synthesis, modification, and biological evaluation of small molecule anti-cancer compounds for breast cancer therapeutic development.